Doer Biologics Completes Phase 2 Enrollment for DR10624 in Severe Hypertriglyceridemia Treatment

Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a biopharmaceutical company in the clinical stage, announced important progress in its innovative approach to treating severe hypertriglyceridemia (SHTG). The company, based in HANGZHOU, China, has successfully completed patient enrollment for its Phase 2 clinical trial of DR10624, a novel therapeutic agent. This biotherapeutic is a tri-specific agonist that targets three receptors: Fibroblast growth factor 21 receptor (FGF21R), Glucagon receptor (GCGR), and Glucagon-like peptide-1 receptor (GLP-1R).

The DR10624-201 study aims to assess the effectiveness and safety of this treatment in adult patients diagnosed with SHTG. These patients exhibit fasting triglyceride levels exceeding 5.65 mmol/L (500 mg/dL). The study is structured as a randomized, placebo-controlled, double-blind trial, spanning 12 weeks and involving 79 participants. This advancement marks a significant step toward addressing the risks associated with SHTG, which include acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD).

Yanshan Huang, Ph.D., the founder and CEO of Doer Bio, emphasized the innovative nature of DR10624 as a first-in-class tri-agonist. Developed using Doer Bio's proprietary MultipleBody® platform technology, DR10624 is engineered for balanced activity against metabolic diseases. The compound has shown remarkable potential in both preclinical and clinical settings, effectively lowering triglyceride levels, normalizing blood lipids, and enhancing liver function.

The successful patient enrollment for the DR10624-201 study was announced by Yongliang Fang, Ph.D., Chief Operating Officer of Doer Bio. Fang highlighted the growing recognition of SHTG as a significant public health issue. SHTG patients face heightened risks of severe conditions, which may lead to hospitalization and even death. The current study seeks to identify the optimal dosage for advancing DR10624 as a pioneering biologic treatment for SHTG patients, with key results anticipated in the third quarter of 2025.

Doer Bio, the company behind these advancements, is focused on developing multi-domain and multi-specific biotherapeutics to address unmet needs in metabolic diseases and cancer treatment. The company boasts several proprietary platform technologies, including xLONGylation®, MultipleBody®, AccuBody®, and SMART-VHHBody.

This development in Doer Bio's clinical trial endeavors represents a promising stride in the biopharmaceutical landscape. Through its innovative platforms and dedication to addressing complex medical conditions, the company continues to push the boundaries of treatment options available for severe metabolic disorders. As the medical community awaits the results of the Phase 2 clinical trial, there is optimism about the potential impact of DR10624 in improving patient outcomes and offering new hope for those with SHTG.

The details of this clinical trial can be accessed at clinicaltrials.gov under the identifier NCT06555640. With a commitment to pioneering therapeutic solutions, Doer Bio remains at the forefront of biopharmaceutical innovation, poised to make significant contributions to public health through its cutting-edge research and development efforts.